Kazyumba G L, Ruppol J F, Tshefu A K, Nkanga N
Laboratoire de Parasitologie, Kinshasa, Zaïre.
Bull Soc Pathol Exot Filiales. 1988;81(3 Pt 2):591-4.
Human African trypanosomiasis (HAT) in Zaïre is a medical problem of first importance, particularly in endemic areas where sleeping sickness threatens about 10 millions of human beings almost the third of the whole population. Used since about forty years as the main trypanocidal drug, melarsoprol is accompanied with a more and more important rate of failures (10%) during the last ten years. 86 patients from whom 51 were refractory with melarsoprol have been treated with difluoromethylornithine (DFMO) since May 1984. Results which have been obtained seem to be encouraging because desperate cases are considered cured after 2 years of set-back. Side effects (disorders of intestinal function, anaemia, drug administration over a long period of time) may be considered as minor.
扎伊尔的人类非洲锥虫病（昏睡病）是一个至关重要的医学问题，尤其是在昏睡病威胁着约1000万人（几乎占总人口的三分之一）的流行地区。美拉胂醇作为主要的杀锥虫药物已使用了约四十年，在过去十年中，其治疗失败率越来越高（达10%）。自1984年5月以来，我们使用二氟甲基鸟氨酸（DFMO）对86例患者进行了治疗，其中51例对美拉胂醇耐药。所获得的结果似乎令人鼓舞，因为一些绝望的病例在经过两年的病情反复后被认为已治愈。副作用（肠道功能紊乱、贫血、长期用药）可被视为轻微。
